ESMO: Pfizer's Lorbrena Makes Case To Claim ALK+ Lung Cancer CROWN
But 'Unique Side Effects' A Concern
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.
